José A. Vázquez

20.7k total citations · 6 hit papers
151 papers, 11.3k citations indexed

About

José A. Vázquez is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, José A. Vázquez has authored 151 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Infectious Diseases, 85 papers in Epidemiology and 18 papers in Pharmacology. Recurrent topics in José A. Vázquez's work include Antifungal resistance and susceptibility (113 papers), Fungal Infections and Studies (56 papers) and Pneumocystis jirovecii pneumonia detection and treatment (29 papers). José A. Vázquez is often cited by papers focused on Antifungal resistance and susceptibility (113 papers), Fungal Infections and Studies (56 papers) and Pneumocystis jirovecii pneumonia detection and treatment (29 papers). José A. Vázquez collaborates with scholars based in United States, Belgium and Spain. José A. Vázquez's co-authors include Jack D. Sobel, Luis Ostrosky‐Zeichner, Peter G. Pappas, Annette C. Reboli, Carol A. Kauffman, Cornelius J. Clancy, Thomas J. Walsh, David R. Andes, Mindy G. Schuster and Kieren A. Marr and has published in prestigious journals such as Journal of Clinical Investigation, Cancer and Clinical Microbiology Reviews.

In The Last Decade

José A. Vázquez

146 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

2015 2.6k citations Peter G. Pappas, Carol A. Kauffman et al. Clinical Infectious Diseases profile →
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

2016 979 citations Peter G. Pappas, Carol A. Kauffman et al. Clinical Infectious Diseases profile →
Candida glabrata : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans

1999 736 citations Paul L. Fidel, José A. Vázquez et al. profile →
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

2007 478 citations Peter G. Pappas, José A. Vázquez et al. Clinical Infectious Diseases profile →
T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial

2015 297 citations Cornelius J. Clancy, Luis Ostrosky‐Zeichner et al. Clinical Infectious Diseases profile →
Identification of COVID-19 can be quicker through artificial intelligence framework using a mobile phone–based survey when cities and towns are under quarantine

2020 238 citations Arni S. R. Srinivasa Rao, José A. Vázquez profile →

Peers

Countries citing papers authored by José A. Vázquez

Since Specialization

Citations

This map shows the geographic impact of José A. Vázquez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José A. Vázquez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José A. Vázquez more than expected).

Fields of papers citing papers by José A. Vázquez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José A. Vázquez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José A. Vázquez. The network helps show where José A. Vázquez may publish in the future.

Co-authorship network of co-authors of José A. Vázquez

This figure shows the co-authorship network connecting the top 25 collaborators of José A. Vázquez. A scholar is included among the top collaborators of José A. Vázquez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José A. Vázquez. José A. Vázquez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chronic Cavitary Pulmonary Histoplasmosis–Novel Concepts Regarding Pathogenesis 2025 ·Journal of Fungi ·John F. Fisher, Michael Saccente, George S. Deepe, Natasha M. Savage, (unknown), José A. Vázquez	0
2	Invasive Aspergillosis in the Intensive Care Unit 2025 ·Journal of Fungi ·(unknown), José A. Vázquez	3
3	Invasive Candidiasis in the Intensive Care Unit: Where Are We Now? 2025 ·Journal of Fungi ·José A. Vázquez, (unknown), (unknown)	6
4	Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study 2025 ·Open Forum Infectious Diseases ·George R. Thompson, Haihui Huang, Sizhou Feng, Yunsong Yu, Àlex Soriano, Oliver A. Cornely, Bart Jan Kullberg, Peter G. Pappas, Marin Kollef, José A. Vázquez, Patrick M. Honoré, Laura A. Cox, Matteo Bassetti	0
5	The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention 2024 ·Open Forum Infectious Diseases ·Jessica S Little, Eleftheria Kampouri, Daniel Friedman, Todd P McCarty, George R. Thompson, Dimitrios P. Kontoyiannis, José A. Vázquez, John W. Baddley, Sarah P. Hammond	26
6	P29 Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data 2024 ·JAC-Antimicrobial Resistance ·Oliver A. Cornely, George R. Thompson, Àlex Soriano, Bart Jan Kullberg, Marin H. Kollef, José A. Vázquez, Patrick M. Honoré, Matteo Bassetti, John Pullman, (unknown), Anita Das, Taylor Sandison, Peter G. Pappas	1
7	Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials 2024 ·Critical Care ·Patrick M. Honoré, Matteo Bassetti, Oliver A. Cornely, Hervé Dupont, Jesús Fortün, Marin H. Kollef, Peter G. Pappas, John Pullman, José A. Vázquez, (unknown), Sara Dickerson, (unknown), Taylor Sandison, George R. Thompson	5
8	P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis 2023 ·JAC-Antimicrobial Resistance ·George R. Thompson, Àlex Soriano, Oliver A. Cornely, Bart Jan Kullberg, Marin H. Kollef, José A. Vázquez, Anita Das, Jeffrey B. Locke, (unknown), Peter G. Pappas	0
9	Efficacy of biofilm disrupters against Candida auris and other Candida species in monomicrobial and polymicrobial biofilms 2023 ·Mycoses ·(unknown), Elias K. Manavathu, (unknown), (unknown), José A. Vázquez	3
10	HIV Treatment Outcomes in Rural Georgia Using Telemedicine 2021 ·Open Forum Infectious Diseases ·(unknown), Moshood Olanrewaju Omotayo, Tae Jin Lee, Arni S. R. Srinivasa Rao, José A. Vázquez	6
11	Perioperative Considerations in Urgent Surgical Care of Suspected and Confirmed COVID-19 Orthopaedic Patients: Operating Room Protocols and Recommendations in the Current COVID-19 Pandemic 2020 ·Journal of the American Academy of Orthopaedic Surgeons ·Mohamed E. Awad, (unknown), José A. Vázquez, John G. DeVine	64
12	637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin 2020 ·Open Forum Infectious Diseases ·José A. Vázquez, Shawn Flanagan, Peter G. Pappas, George R. Thompson, Taylor Sandison, Patrick M. Honoré	3
13	Significant effect of HIV/HAART on oral microbiota using multivariate analysis 2019 ·Scientific Reports ·Ann L. Griffen, (unknown), Clifford J. Beall, Elizabeth A. Lilly, (unknown), (unknown), (unknown), Shahr B. Hashmi, Chiranjit Mukherjee, (unknown), José A. Vázquez, Michael E. Hagensee, Eugene J. Leys, Paul L. Fidel	25
14	Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates 2014 ·Antimicrobial Agents and Chemotherapy ·Gregory Eschenauer, M. Hong Nguyen, Shmuel Shoham, José A. Vázquez, Arthur J. Morris, William Pasculle, Christine J. Kubin, Kenneth Klinker, Peggy L. Carver, Kimberly E. Hanson, Sharon Chen, Simon W. Lam, Brian A. Potoski, Lloyd Clarke, Ryan K. Shields, Cornelius J. Clancy	54
15	Diagnosing and managing oropharyngeal candidiasis 2007 ·José A. Vázquez	6
16	The safety of anidulafungin 2006 ·Expert Opinion on Drug Safety ·José A. Vázquez	14
17	Multicenter Clinical Evaluation of the (1->3) -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans 2005 ·Clinical Infectious Diseases ·Luis Ostrosky‐Zeichner, Barbara D. Alexander, Daniel H. Kett, José A. Vázquez, Peter G. Pappas, (unknown), Paul A. Ketchum, John R. Wingard, R.I. Schiff, Hiroshi Tamura, Malcolm Finkelman, John Rex	496
18	Epidemiology of Yeast Colonization in the Intensive Care Unit 2000 ·European Journal of Clinical Microbiology & Infectious Diseases ·S. Hedderwick, Michael J. Lyons, (unknown), José A. Vázquez, Carol A. Kauffman	62
19	Revisión : proteína de pescado y metabolismo del colesterol 1994 ·José A. Vázquez, Francisco J. Sánchez‐Muniz	4
20	A Concentrated Mixture of Amino Acids and Dipeptides for Total Parenteral Nutrition 1986 ·Transfusion Medicine and Hemotherapy ·José A. Vázquez, (unknown), Herbert Lochs, Klaus Langer, Maria T. Brandl, Siamak A. Adibi	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact